Revenue grew 4.93% to ¥4.60 billion, with net profit down 13.55% to ¥940 million. Blood products and vaccines both saw revenue growth, while R&D investment increased and a high dividend payout was maintained.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.